Mark R. Albertella

AstraZeneca

H指数:18

被引数:2,838

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

乳腺癌的同源重组缺陷和半合子驱动抵抗

Nature

IF48.5

2026-03-040

OAAI

Anton Safonov; Minna Lee; David N. Brown; Luca Boscolo Bielo; Miika Mehine; Chaitanya Bandlamudi; Ben O’Leary; Hong Shao; Laia Vicente; Daniel Muldoon; Allen Zhu; Susana Ros; Antonio Marra; Pier Selenica; Ivan Bieche; Bradley Wubbenhorst; Emanuela Ferraro; Laura Courtois; Rania El Botty; Mehnaj Ahmed; Enrico Moiso; Julia Ah-Reum An; Mark T. A. Donoghue; Marie Will; Fresia Pareja; Emily Nizialek; Natalia Lukashchuk; Eleni Sofianopoulou; Yuan Liu; Xin Huang; Colombe Chappey; Anna D. Staniszewska; Dara Ross; Diana Mandelker; Marc Ladanyi; Nikolaus Schultz; Michael F. Berger; Maurizio Scaltriti; Jorge S. Reis-Filho; Bob T. Li; Kenneth Offit; Larry Norton; Ronglai Shen; Kara N. Maxwell; Fergus Couch; Susan M. Domchek; Elisabetta Marangoni; Sohrab Shah; Mark R. Albertella; Violeta Serra; Britta Weigelt; David B. Solit; Katherine L. Nathanson; Mark E. Robson; Nicholas C. Turner; Sarat Chandarlapaty; Pedram Razavi

Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells

PARP1捕获作为BRCA突变癌细胞中PARP抑制剂疗效驱动因素的遗传证据

NUCLEIC ACIDS RESEARCH

IF13.1

2025-12-110

PRE

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair

雄激素受体抑制在前列腺癌模型中扩展了PARP抑制剂的活性，超越了BRCA突变和同源重组修复缺陷。

NAR CANCER

IF3.2

2025-12-010

OAAI

Addressing Project Optimus: Preclinical, modelling and clinical data to support identification of the Recommended Phase 2 Dose for saruparib

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-010

PRE

Structural variants of BRCA1/2 represent a novel biomarker of homologous recombination deficiency in multiple tumour types

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-010

PRE

Synergistic antitumor effect of FRa TOP1i antibody drug conjugate, AZD5335, in combination with the PARP1 inhibitor, saruparib (AZD5305), in preclinical models of ovarian cancer

CANCER RESEARCH

IF16.6

2024-04-050

PRE

MALT1 inhibition suppresses antigen-specific T cell responses

MALT1抑制抑制抗原特异性T细胞反应

CELLULAR IMMUNOLOGY

IF2.9

2024-03-010

OAAI

Combination of the PARP1-selective inhibitor AZD5305 with the ATR inhibitor ceralasertib for the treatment of PARPi-resistant cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-12-010

PRE

Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity

抑制METTL3导致细胞内在的干扰素反应，从而增强抗肿瘤免疫力

CANCER DISCOVERY

IF33.3

2023-08-0729

PRE

Guirguis, Andrew A.; Ofir-Rosenfeld, Yaara; Knezevic, Kathy; Blackaby, Wesley; Hardick, David; Chan, Yih-Chih; Motazedian, Ali; Gillespie, Andrea; Vassiliadis, Dane; Lam, Enid Y. N.; Tran, Kevin; Andrews, Byron; Harbour, Michael E.; Vasiliauskaite, Lina; Saunders, Claire J.; Tsagkogeorga, Georgia; Azevedo, Aleksandra; Obacz, Joanna; Pilka, Ewa S.; Carkill, Marie; Macpherson, Laura; Wainwright, Elanor N.; Liddicoat, Brian; Blyth, Benjamin J.; Albertella, Mark R.; Rausch, Oliver; Dawson, Mark A.

A Quantitative Systems Pharmacology (QSP) model to characterize dosedependent antitumor activity of AZD5305, PARP1 selective inhibitor, across multiple xenograft models

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Preclinical evaluation of a novel B7-H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade

CANCER RESEARCH

IF16.6

2023-04-040

PRE

STC-15, AN ORAL SMALL MOLECULE INHIBITOR OF THE RNA METHYLTRANSFERASE METTL3, INHIBITS TUMOUR GROWTH THROUGH ACTIVATION OF ANTI-CANCER IMMUNE RESPONSES AND SYNERGISES WITH IMMUNE CHECKPOINT BLOCKADE

JOURNAL FOR IMMUNOTHERAPY OF CANCER